Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $997.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price hoisted by stock analysts at Leerink Partners from $835.00 to $997.00 in a research note issued on Monday, Benzinga reports. The firm currently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Partners‘s price objective points to a potential upside of 3.41% from the company’s current price.

Several other research analysts have also weighed in on the company. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Truist Financial boosted their price target on Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the company a “buy” rating in a research report on Monday. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research note on Tuesday, July 7th. Raymond James Financial raised their price objective on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Piper Sandler lifted their price objective on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an “overweight” rating in a research note on Monday, October 19th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $898.97.

Regeneron Pharmaceuticals Trading Up 3.9%

REGN stock traded up $36.24 on Monday, hitting $964.13. 1,196,366 shares of the company were exchanged, compared to its average volume of 824,106. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The stock has a market capitalization of $99.27 billion, a price-to-earnings ratio of 21.26, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a twelve month low of $591.52 and a twelve month high of $974.00. The business’s fifty day moving average is $793.30 and its two-hundred day moving average is $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. During the same quarter last year, the business earned $11.83 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% on a year-over-year basis. As a group, research analysts forecast that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Huda Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This represents a 31.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock valued at $6,506,845 in the last quarter. Company insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. State Street Corp lifted its position in shares of Regeneron Pharmaceuticals by 3.6% during the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Regeneron Pharmaceuticals by 8.5% during the second quarter. Bank of America Corp DE now owns 1,291,053 shares of the biopharmaceutical company’s stock worth $805,023,000 after purchasing an additional 101,469 shares in the last quarter. Amundi boosted its stake in shares of Regeneron Pharmaceuticals by 0.4% in the second quarter. Amundi now owns 1,013,540 shares of the biopharmaceutical company’s stock valued at $631,983,000 after purchasing an additional 3,742 shares during the period. Finally, Legal & General Group Plc purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $473,872,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported third-quarter earnings of $20.07 per share, well above the $16.51 consensus estimate, while revenue rose 36% year over year to $5.12 billion versus expectations of $4.58 billion. The results were supported by strong Dupixent performance and a larger Sanofi profit share. These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
• Positive Sentiment: Analysts broadly raised their targets following the earnings beat. Guggenheim lifted its target to $1,100 and maintained a buy rating, JPMorgan raised its target to $1,050 with an overweight rating, and Bank of America increased its target to $1,030 with a buy rating. Truist also raised its target to $982 and kept a buy rating.
• Positive Sentiment: The company’s pipeline and commercial outlook remain additional catalysts, with stronger Libtayo data in high-risk skin cancer and an expanded BARDA supply agreement for Ebola treatment highlighting potential future growth. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Positive Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3 to shareholders of record November 20. The dividend provides a modest ongoing shareholder return, although the annualized yield is approximately 0.4%.
• Neutral Sentiment: Not all analysts view the recent rally as fully supported by near-term upside. Morgan Stanley, Wells Fargo, Bernstein, RBC and Baird raised their targets but retained equal-weight, market-perform, sector-perform or neutral ratings; their targets remain below the current trading level.
• Negative Sentiment: The stock’s sharp advance has increased valuation and execution concerns. Several firms’ targets imply downside, suggesting investors may already be pricing in much of the recent earnings improvement and Dupixent momentum.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.